Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-Host Disease without Delaying Immune Reconstitution
Authors:
- Morton J. CowanMCMorton J. Cowan
- Christopher C. DvorakCDChristopher C. Dvorak
- Lisa MusickLMLisa Musick
- Janel R. Long-BoyleJLJanel R. Long-Boyle
- Lee Ann Baxter-LoweLBLee Ann Baxter-Lowe
- Biljana HornBHBiljana Horn
Open Access
- 1 November 2012
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 18 (11) , 1656-1663
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- A pilot study of reduced toxicity conditioning with BU, fludarabine and alemtuzumab before the allogeneic hematopoietic SCT in children and adolescentsBone Marrow Transplantation, 2010
- Hematopoietic Stem Cell Transplantation for Hemoglobinopathies: Current Practice and Emerging TrendsPediatric Clinics of North America, 2010
- Current International Perspectives on Hematopoietic Stem Cell Transplantation for Inherited Metabolic DisordersPediatric Clinics of North America, 2010
- Hematopoietic Stem Cell Transplantation for LeukemiaPediatric Clinics of North America, 2010
- Targeting of Natural Killer Cells by Rabbit Antithymocyte Globulin and Campath-1H: Similar Effects Independent of SpecificityPLOS ONE, 2009
- Hematopoietic Stem Cell Transplantation for Bone Marrow Failure Syndromes in ChildrenTransplantation and Cellular Therapy, 2009
- Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CMLBone Marrow Transplantation, 2005
- Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioningBlood, 2004
- Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complicationsBlood, 2003
- Reshaping human antibodies for therapyNature, 1988